Early Access to Medicines Scheme: Overview

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides this guidance for the Early Access to Medicines Scheme (EAMS), a voluntary program designed to give patients with life-threatening or debilitating conditions access to innovative treatments before they receive formal marketing authorization. The regulatory framework is governed by Regulation 167C(1) of The Human Medicines Regulations 2012 and the 2022 Amendments. To participate, pharmaceutical companies must undergo a two-step evaluation: securing a Promising Innovative Medicine (PIM) designation and obtaining a Scientific Opinion. This opinion, which assesses the benefit-risk balance, is valid for one year and supports prescribing by healthcare professionals. While this document is general guidance and does not detail specific company violations or individual inspection dates, it mandates that all applying companies adhere to a strict submission calendar, with cycles scheduled through 2028. Required actions for applicants include paying non-refundable fees and providing comprehensive data to justify medical necessity. The MHRA emphasizes that this scheme does not replace standard licensing but offers a pathway for addressing unmet medical needs through established treatment protocols and public assessment reports.